Figure 2From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome Prognostic significance by modified NIH criteria in test (A) and validation (B) cohort, tumor size sub-groups in test (C) and validation (D) cohort, mitosis count sub-groups in test (E) and validation (F) cohort and serosal invasion sub-groups in test (G) and validation (H) cohort in GISTs. Back to article page